ABSTRACT
No abstract available.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , CD4 Antigens/metabolism , CD56 Antigen/metabolism , Bone Marrow/metabolism , Dendritic Cells/cytology , Diagnostic Errors , Exons , Flow Cytometry , Gene Rearrangement , Hematologic Neoplasms/diagnosis , Histone-Lysine N-Methyltransferase/genetics , Immunohistochemistry , In Situ Hybridization, Fluorescence , Leukemia, Myeloid, Acute/diagnosis , Myeloid-Lymphoid Leukemia Protein/genetics , Real-Time Polymerase Chain Reaction , Sequence Analysis, DNA , Transcription Factors/genetics , Translocation, GeneticABSTRACT
BACKGROUND: The Dia antigen has been found to have a relatively higher incidence among Korean populations. However, the current popular antibody screening panels contain no Dia positive cells. To prevent hemolytic transfusion reaction, screening for unexpected antibody plus screening for Dia positive cells should be performed. In this study, we evaluate the performance of the 3% Surgiscreen Sub-code D (Ortho-Clinical Diagnostics, USA) manufactured as a 3-cell panel including Dia cell versus the ID-DiaCell I-II (DiaMed, Switzerland) as a 2-cell panel plus ID-DiaCell Dia+ (DiaMed, Switzerland) in screening for irregular red blood cell alloantibodies. METHODS: From December 13, 2013 to April 24, 2014, we tested the 3% Surgiscreen by the AutoVue Innova system and the ID-DiaCell in parallel to evaluate reagent sensitivity in detecting irregular antibodies in multi-transfused patients' plasma or serum. Identification of unexpected antibody tests was performed for positive screening results. RESULTS: Antibody-positive rates were 4.2% (79/1885) and 4.6% (87/1885) for antibody screening with the 3% Surgiscreen and the ID-DiaCell, respectively. Among the 1885 samples, 1875 (99.5%) showed concordant results between the 2 methods, while 10 results differed. From the 10 discrepancies, 1 result was positive only on the 3% Surgiscreen. The prevalence of anti-Dia antibody was 10.1% and 9.2% in the 3% Surgiscreen and the ID-DiaCell, respectively. CONCLUSION: The 3% Surgiscreen manufactured as 3-cell showed a high concordance rate ompared to standard methods. The prevalence of anti-Dia showed no difference between the 2 reagents.
Subject(s)
Humans , Antibodies , Blood Group Incompatibility , Erythrocytes , Incidence , Indicators and Reagents , Isoantibodies , Mass Screening , Plasma , PrevalenceABSTRACT
The corresponding author of above article should be corrected to Hyung-Hoi Kim.